In The Media

Jeffrey Kraws, Crystal Research Associates Sr. Pharmaceutical Analyst, Scott Henry, Oppenheimer & Co Pharmaceutical Analyst, and CNBC's Carl Quintanilla

Jeffrey Kraws  discussing upcoming earnings reports for the pharmaceutical sector.

Jeffrey Kraws discussing the impacts of safety concerns that were released over the weekend for GlaxoSmithKline's diabetes drug, Avandia. 

Tips on making money in the drug sector, with Michael Krensavage, Raymond James pharmaceutical analyst; Jeffrey Kraws, Crystal Research Assoc. sr. pharmaceutical analyst; and CNBC's Liz Clamanpharmaceutical analyst; and CNBC's Liz Claman

Investors wiped some 6 billion euros off the market value of French pharmaceutical company Sanofi-Aventis Thursday after the FDA rejected its weight-loss drug. CNBC's Guy Johnson talks of Sanofi's woes with Andrew Fellows, Analyst at Helvea, and Jeff...

December 24: Part 2 of 2 of Jeff Kraws' interview on Bloomberg Television discussing the healthcare reform bill, which cleared the Senate this morning. In this segment, Mr. Kraws overviews some of the short- and long-term impacts of this legislation ...

December 24: Part 1 of 2: Crystal Research Associates CEO and Senior Research Analyst, Jeffrey Kraws, appeared on Bloomberg Television discussing the winners and losers of the Senate's final 60-39 vote for the healthcare reform legislation. Mr. Kraws...

On January 20, 2010, Crystal Research CEO and Senior Analyst Jeff Kraws was interviewed on Bloomberg Television discussing the impacts that Republican Scott Brown's victory in the Massachusetts Senate race may have on healthcare reform.

On November 9, Jeffrey Kraws, CEO and cofounder of Crystal Research Associates, appeared on Bloomberg Television discussing the impacts of the healthcare reform bill passed Nov. 8 in the US House of Representatives.

On Wednesday, July 22 (Bloomberg TV) -- Jeffrey Kraws, Chief Executive Officer and co-founder of Crystal Research Associates, was featured on Bloomberg TV discussing healthcare reform and its potential impact on society, including its effects on phar...

July 6: Jeffrey Kraws, Senior Research Analyst and Cofounder of Crystal Research Associates, appeared Monday, July 6, 2009, on Bloomberg Television discussing healthcare reform, its impact on drug maker profits, and consolidation within the pharmaceu...

June 10 (Bloomberg) -- Jeffrey Kraws, Senior Research Analyst and Cofounder of Crystal Research Associates, appeared Wednesday, June 10, 2009, on Bloomberg Television discussing healthcare reform and its impact on the pharmaceutical sector. Mr. Kraws...

May 18 (Bloomberg) -- Jeffrey Kraws, Senior Research Analyst and Cofounder of Crystal Research Associates, appeared Monday, May 18, 2009, on Bloomberg Television discussing drug companies that are well positioned to develop a vaccine against the H1N1...

Apr. 28 (Bloomberg) -- Jeffrey Kraws, Senior Research Analyst and Cofounder of Crystal Research Associates, appeared Tuesday, April 28, 2009, on Bloomberg Television discussing Pfizer's earnings preview, pharma updates, and the impact of the swine fl...

Mar. 9 (Bloomberg) -- Jeffrey Kraws, Senior Research Analyst at Crystal Research Associates, appeared on Monday, March 9, 2009, on Bloomberg Television discussing the Continued Consolidation in the Pharmaceutical Industry.

Jan. 26 (Bloomberg) -- Jeffrey Kraws, chief executive officer and co-founder of Crystal Research Associates, talks with Bloomberg's Carol Massar about Pfizer Inc.'s agreement to buy Wyeth for about $68 billion in the largest pharmaceutical acquisitio...

Jan. 19 (Bloomberg) -- Jeffrey Kraws, chief executive officer and co-founder of Crystal Research Associates, talks with Bloomberg's Deirdre Bolton about the investment appeal of companies that make generic drugs. Kraws also discusses the outlook for ...

Jeffrey Kraws on Bloomberg Television discussing Johnson and Johnson Earnings

07-23-2009 (FOX Business)--Crystal Research Associates CEO and co-founder, Jeff Kraws, spoke with Dow Jones Consumer Health Columnist Anna Mathews, Small Business Owner Ron Mitchell, and Writer and Comedian Craig Baldo on how pharmaceutical and other...

07/23/2009 (FOX Business Network)--Part 2--Jeffrey Kraws, the CEO and co-founder of Crystal Research Associates, participates in the second half of a panel on Fox Business discussing pharamcuetical companies' and small business owners' views on healt...

On January 21, 2010, Jeff Kraws, CEO and cofounder of Crystal Research Associates, was interviewed by FOX Business Television discussing the current status of the H1N1 pandemic and its effect on several pharmaceutical companies, which have been exper...

07/23/2009 (FOX Business Network)--Crystal Research Associates CEO and co-founder Jeffrey Kraws discusses Bristol-Myers Squibb's 2Q earnings report and $2.1 billion acquisition of Medarex.

On Tuesday, July 21 (FOX Business) -- Jeffrey Kraws, Chief Executive Officer and co-founder of Crystal Research Associates, talks with FOX Business' Money for Breakfast, Rep. Peter Welch, (D-VT), and Mount Sinai Medical Center Oncologist Dr. Cynara C...

April 16: Jeffrey Kraws, Senior Research Analyst and Cofounder at Crystal Research Associates, appeared on FOX Business Television's Money for Breakfast segment to discuss Johnson & Johnson versus Merck.

Feb. 3 (FOX Business) -- Jeffrey Kraws, chief executive officer and co-founder of Crystal Research Associates, talks with FOX Business' Money for Breakfast about current challenges facing the pharmaceutical sector.

Wealth Strategies, February 13, 2013

Jeff Kraws sits down with Thomson Reuters' Rhonda Schaffler; David Joy, Chief Market Strategist of Ameriprise Financial; and Craig Irwin, Senior Vice President at Wedbush Securities to break down President Obama's 2/12/2013 State of the Union address. Topics discussed include the technology, energy, and healthcare sectors.

Reuters, Obamacare Ruling Winners and Losers, June 28, 2012

Jeff Kraws spoke with Reuters' Rhonda Schaffler about winners and losers of this morning's landmark Supreme Court ruling to uphold Obamacare's individual mandate. He pointed out specific stocks to watch and discusses sector trends for healthcare insurers, hospitals, pharma and biotech companies, medical records, medical schools, generics, and medical device...

In just six months, drug companies have spent $221 billion buying each  other, with a lot of recent mergers being between biotech firms. So what  is driving the deals? Business television show Arise Xchange sits down  with Jeff Kraws, Cofounder and CEO of Crystal Research Associates, to  discuss.

In the wake of a new report from the British government stating that antibiotic-resistant infections could kill 10 million people each year by the year 2050, senior pharmaceutical analyst Jeff Kraws of Crystal Research Associates sits down with host Akhtar Khan of Arise Xchange to discuss the report's projections and impacts of increasing drug resistance on the pharmaceutical industry and on consumers.

Crystal Research CEO Jeff Kraws speaks with Arise XChange's Andrew Schmertz about the Ebola virus and current efforts by drugmakers to create Ebola therapeutics and vaccines (10/14/2014).

Crystal Research CEO Jeff Kraws speaks with Arise XChange's Andrew Schmertz about recent M&A activity in the pharmaceutical industry (4/30/2014).

Marcum Conference, May 30, 2013

Henry Truc from Equities.com chats with Jeffery Kraws and discusses Crystal Research's innovative equity research and side by side analysis.